BioCryst Pharmaceuticals BCRX Business Segments — SG&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's business segments — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's business segments — SG&A?
- BioCryst Pharmaceuticals (BCRX) reported business segments — SG&A of $42.95M in Q1 2026.
- How has BioCryst Pharmaceuticals's business segments — SG&A changed year-over-year?
- BioCryst Pharmaceuticals's business segments — SG&A decreased by 9.9% year-over-year, from $47.67M to $42.95M.
- What is the long-term trend for BioCryst Pharmaceuticals's business segments — SG&A?
- Over 2 years (2022 to 2024), BioCryst Pharmaceuticals's business segments — SG&A has grown at a 29.2% compound annual growth rate (CAGR), from $159.37M to $266.13M.
- What does business segments — SG&A mean?
- Aggregates the operating expenses required to support the segment's commercial activities, corporate overhead, and administrative functions. It is a critical measure of the operational cost structure required to sustain and grow the business.